Successful Clinical Study NKP-1339/IT-139

27.10.2011

A Phase I clinical study conducted in the USA has shown the cancer-inhibiting effect and good tolerability of the ruthenium compound NKP1339/IT-139, the most promising project of the research platform "Translational Cancer Therapy Research".

Niiki Pharma Announces Positive Interim Data from Ongoing Clinical Trial of Novel Anti-Cancer Agent NKP-1339 (Press release, 20.9.2011)
Im Kampf gegen den Krebs (uni:view Magazin, 27.9.2011, in German)
Wiener Chemiker entwickelten Anti-Krebs-Wirkstoff auf Ruthenium-Basis (Medical University of Vienna, 29.8.2012, in German)

Back